A surprising new study suggests that testosterone, often viewed as a hormone tied to prostate cancer risk, may actually play a protective role against one of the deadliest brain cancers in men. Published in Nature on May 6, 2026, the NIH-funded research from Cleveland Clinic could reshape how doctors approach treatment for glioblastoma, an aggressive brain tumor that has long been more lethal in men than women.
Why Glioblastoma Hits Men Harder
Glioblastoma is the most common and aggressive primary brain tumor in adults. According to the National Cancer Institute, men are roughly 1.6 times more likely than women to develop the disease, and they tend to have shorter survival times after diagnosis. The reasons behind this sex disparity have puzzled oncologists for decades, with theories ranging from genetics to differences in immune response.
The new Cleveland Clinic study, led by Justin Lathia, Ph.D., Scientific Director of the Brain Tumor Center, points to an unexpected culprit: low testosterone. When researchers tracked clinical outcomes in more than 1,300 men with glioblastoma using the NIH’s Surveillance, Epidemiology, and End Results (SEER) database, they found that those receiving testosterone supplementation had a 38% lower risk of death compared with men who did not.
The Stress-Hormone Connection
To understand why, the team turned to preclinical mouse models. Tumors grew faster and more aggressively in male mice with low testosterone. The mechanism, the researchers report, runs through the body’s primary stress-response system — the hypothalamus-pituitary-adrenal (HPA) axis.
When testosterone levels in the brain drop, the HPA axis ramps up production of glucocorticoid stress hormones such as corticosterone (the rodent equivalent of cortisol). These hormones, in turn, create an immunosuppressive environment that blocks T cells and other immune defenders from reaching the tumor. Without immune surveillance, glioblastoma cells proliferate unchecked.
Notably, the effect appears to be male-specific. Female mice did not show the same pattern, suggesting that sex hormones, brain biology, and immune signaling interact in ways researchers are only beginning to map.
A “Welcome Surprise”
The finding flips a long-held assumption that androgens — the family of male sex hormones that includes testosterone — generally fuel cancer growth. In prostate cancer, for example, androgen deprivation therapy is a cornerstone of treatment. The new data suggests the brain may operate by very different rules.
“This outcome is a welcome surprise and may potentially offer a lead for new treatments,” Anthony Letai, M.D., Ph.D., director of the National Cancer Institute, noted in commentary accompanying the release.
Could Testosterone Become Part of Brain Cancer Care?
The researchers caution that the work is preclinical and observational at this stage, and they are not recommending testosterone supplementation as a stand-alone glioblastoma therapy. But the consistency between the mouse models and the human SEER data is striking enough that clinical trials are being planned.
Several open questions remain:
- Dosing and safety. Testosterone therapy carries known risks, including potential effects on cardiovascular health, red blood cell counts, and prostate tissue. Whether brain-cancer patients could safely receive doses sufficient to suppress tumor growth has yet to be established.
- Timing. Should testosterone be considered during initial treatment, after surgery, or only in patients with documented low levels? The studies have not yet answered this.
- Interaction with immunotherapy. Because the proposed mechanism involves immune suppression, testosterone could potentially enhance the effectiveness of immune-checkpoint inhibitors — but this combination must be tested rigorously.
- Implications for androgen deprivation. Men being treated with androgen-blocking drugs for prostate cancer may face higher glioblastoma risk if they later develop a brain tumor. Research is needed to weigh those trade-offs.
What This Means for Men’s Health More Broadly
Beyond brain cancer, the study adds to a growing body of research suggesting testosterone has wide-ranging effects on immune function, inflammation, and stress biology. Earlier work has linked low testosterone in older men to higher rates of cardiovascular events, metabolic syndrome, and depression, though causality in those associations remains contested.
The new findings underscore why physicians increasingly view hormonal balance as a whole-body issue rather than a narrow concern of reproductive health. Levels naturally decline with age — research from the Journal of Clinical Endocrinology & Metabolism indicates total testosterone falls by roughly 1% per year after age 30 — but lifestyle factors also matter. Sleep deprivation, chronic stress, obesity, and certain medications can all suppress production.
Lifestyle Foundations That Support Hormonal Health
While no diet or exercise plan substitutes for medical evaluation, peer-reviewed studies suggest several habits associate with healthier testosterone profiles:
- Strength training and high-intensity exercise. Resistance training has been shown to acutely raise testosterone, and regular activity correlates with higher baseline levels.
- Adequate sleep. A study in JAMA found that just one week of sleep restriction (5 hours per night) reduced daytime testosterone in healthy young men by 10–15%.
- Maintaining a healthy weight. Excess adipose tissue increases aromatase activity, converting testosterone to estrogen.
- Managing chronic stress. Persistently elevated cortisol can blunt testosterone production — the same HPA-axis mechanism implicated in the glioblastoma study.
- Diet quality. Diets rich in zinc, vitamin D, and healthy fats are linked with better hormonal markers in observational studies.
The Bigger Picture
The Cleveland Clinic findings are part of a broader shift in oncology toward sex-specific medicine. Cancer biology, drug metabolism, and immune response can differ substantially between men and women, and treatments calibrated to one sex may underperform — or even backfire — in the other. The American Society of Clinical Oncology has called for more sex-stratified clinical trials, and studies like this one show why.
For now, the message for men diagnosed with glioblastoma is one of cautious optimism: a hormone many of them already make may, with the right protocols, become an ally rather than a bystander. Trials in the next several years will test whether the mouse data translates to patients.
If you or a loved one is navigating a glioblastoma diagnosis, or are considering testosterone therapy for any reason, talk with an oncologist or endocrinologist who can review your individual risk profile, lab results, and treatment goals.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.